A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Trial Profile

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 18 Jan 2017 Status changed from completed to discontinued.
    • 04 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top